{
  "trial_id": "NCT00962624",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Aged 18-65 years of age",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Who have given written informed consent after the nature of the study has been explained.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Who work within the Manchester Medical Microbiology Partnership and may be at potential occupational exposure to meningococci.",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "The possibility of pregnancy",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "A serious chronic disease including progressive neurological disease or seizure disorder.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Have a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component.",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "The patient has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%. He was treated with plasma exchange and corticosteroids for atypical hemolytic uremic syndrome.",
  "_meta": {
    "topic_id": "68",
    "trial_id": "NCT00962624",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}